Literature DB >> 8040670

Incidence of multiple myeloma in Olmsted County, Minnesota: 1978 through 1990, with a review of the trend since 1945.

R A Kyle1, C M Beard, W M O'Fallon, L T Kurland.   

Abstract

PURPOSE: Incidence rates of multiple myeloma appear to have increased in recent decades, but it is difficult to compare the incidence rates over time because of changes in laboratory procedures, differences in diagnostic criteria, and variations in indexing of medical records. However, Olmsted County, Minnesota, provides a rare opportunity to minimize these limitations, because the medical care has been provided mainly by the Mayo Clinic. PATIENTS AND METHODS: Records of Olmsted County residents with a diagnosis of multiple myeloma from January 1, 1978 through December 31, 1990 were reviewed. Criteria for diagnosis and residency were the same as in previous Olmsted County studies.
RESULTS: The incidence rate per 100,000 age-adjusted to the 1950 United States white population was 5.4 for males and 2.8 for females; the overall rate was 4.1. The rates were age-adjusted to the 1950 United States population for comparison with earlier data from this population. The rates increased with age for both sexes. There was no significant change in incidence rates from 1945 through 1990. A comparison of the median age for Olmsted County patients with the age of those referred to the Mayo Clinic from elsewhere indicated that the local patients were appreciably older (74 v. 62 years, respectively). Thirty-two of 55 patients (58%) with multiple myeloma from 1978 through 1990 had a monoclonal plasma-cell proliferative process before the diagnosis of multiple myeloma.
CONCLUSION: The incidence rate of multiple myeloma in Olmsted County, Minnesota, has not changed significantly during the past 46 years. We believe that reports of increasing rates over time are mainly due to improved case ascertainment.

Entities:  

Mesh:

Year:  1994        PMID: 8040670     DOI: 10.1200/JCO.1994.12.8.1577

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  7 in total

1.  Robert Arthur Kyle, MD: a conversation with the editor.

Authors:  Robert Arthur Kyle; William Clifford Roberts
Journal:  Proc (Bayl Univ Med Cent)       Date:  2010-10

2.  Phase II trial of high-dose dexamethasone for untreated patients with primary systemic amyloidosis.

Authors:  M A Gertz; M Q Lacy; J A Lust; P R Greipp; T E Witzig; R A Kyle
Journal:  Med Oncol       Date:  1999-07       Impact factor: 3.064

3.  Patterns of multiple myeloma during the past 5 decades: stable incidence rates for all age groups in the population but rapidly changing age distribution in the clinic.

Authors:  Ingemar Turesson; Ramon Velez; Sigurdur Y Kristinsson; Ola Landgren
Journal:  Mayo Clin Proc       Date:  2010-03       Impact factor: 7.616

4.  Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance.

Authors:  S Vincent Rajkumar; Robert A Kyle; Terry M Therneau; L Joseph Melton; Arthur R Bradwell; Raynell J Clark; Dirk R Larson; Matthew F Plevak; Angela Dispenzieri; Jerry A Katzmann
Journal:  Blood       Date:  2005-04-26       Impact factor: 22.113

5.  Is there a role for 'modified VAD' in the treatment of multiple myeloma?

Authors:  A Agazzi; S Sammassimo; D Laszlo; Sj Liptrott; R Cascio; A Alietti; C Rabascio; P Mancuso; G Pruneri; G Martinelli
Journal:  Ecancermedicalscience       Date:  2009-06-04

6.  Citrullination of histone H3 drives IL-6 production by bone marrow mesenchymal stem cells in MGUS and multiple myeloma.

Authors:  G McNee; K L Eales; W Wei; D S Williams; A Barkhuizen; D B Bartlett; S Essex; S Anandram; A Filer; P A H Moss; G Pratt; S Basu; C C Davies; D A Tennant
Journal:  Leukemia       Date:  2016-07-11       Impact factor: 11.528

Review 7.  Cancer-Cell-Derived IgG and Its Potential Role in Tumor Development.

Authors:  Said Kdimati; Christina Susanne Mullins; Michael Linnebacher
Journal:  Int J Mol Sci       Date:  2021-10-27       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.